Susquehanna Fundamental Investments LLC Acquires Shares of 93,480 2seventy bio, Inc. (NASDAQ:TSVT)

Susquehanna Fundamental Investments LLC purchased a new position in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 93,480 shares of the company's stock, valued at approximately $275,000. Susquehanna Fundamental Investments LLC owned approximately 0.18% of 2seventy bio as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of 2seventy bio in the 4th quarter valued at about $32,000. Raymond James Financial Inc. purchased a new position in 2seventy bio in the fourth quarter worth approximately $52,000. Intech Investment Management LLC grew its holdings in 2seventy bio by 41.1% during the 4th quarter. Intech Investment Management LLC now owns 20,688 shares of the company's stock worth $61,000 after acquiring an additional 6,030 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of 2seventy bio by 23.2% in the 4th quarter. Wells Fargo & Company MN now owns 32,532 shares of the company's stock valued at $96,000 after purchasing an additional 6,133 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of 2seventy bio by 9.5% in the 4th quarter. Rhumbline Advisers now owns 84,670 shares of the company's stock valued at $249,000 after purchasing an additional 7,379 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other 2seventy bio news, CEO William D. Baird III sold 5,092 shares of 2seventy bio stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $25,205.40. Following the transaction, the chief executive officer now directly owns 1,121,034 shares in the company, valued at approximately $5,549,118.30. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The disclosure for this sale can be found here. Insiders have sold 5,152,093 shares of company stock valued at $25,400,018 in the last ninety days. 7.20% of the stock is currently owned by company insiders.

2seventy bio Price Performance

Shares of TSVT traded down $0.01 during midday trading on Friday, reaching $4.99. 347,586 shares of the stock were exchanged, compared to its average volume of 622,186. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $5.30. The company has a market capitalization of $265.62 million, a price-to-earnings ratio of -2.68 and a beta of 1.04. The business's 50-day moving average price is $4.79 and its 200 day moving average price is $3.76.

2seventy bio (NASDAQ:TSVT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.11. 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. The firm had revenue of $22.94 million for the quarter, compared to the consensus estimate of $13.96 million. As a group, equities research analysts expect that 2seventy bio, Inc. will post -1.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TSVT shares. Leerink Partners reiterated a "market perform" rating and set a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Leerink Partnrs cut 2seventy bio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 11th. Morgan Stanley cut their target price on 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Friday, March 14th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 2seventy bio in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $4.25.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.